We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Solventum (SOLV - Free Report) . Shares have added about 11.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Solventum due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Solventum Corporation before we dive into how investors and analysts have reacted as of late.
Solventum Q2 Earnings & Revenues Beat Estimates
Solventum reported second-quarter 2026 adjusted earnings per share of $2.55, which beat the Zacks Consensus Estimate of $1.91 by 33.5%. The bottom line improved 50.9% year over year.
GAAP earnings per share in the quarter was 53 cents compared with 51 cents in the year-ago quarter.
SOLV's Sales Gain From Advance Ordering
Revenues of $2.21 billion rose 2.2% and surpassed the consensus mark of $2.17 billion by 2%. Organic sales increased 9.5%, aided by strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.
Reported growth included a 100-basis-point currency benefit and an 830-basis-point headwind from acquisitions and divestitures. The latter mainly reflected the September 2025 sale of the Purification and Filtration business, partly offset by the Acera acquisition.
Management estimated normalized organic growth of about 4%. This adjusts for roughly 630 basis points of ERP-related advance orders, partly offset by about 100 basis points of SKU rationalization headwinds and a partial separation-timing benefit.
Solventum's MedSurg Business Shows Strength
MedSurg revenues totaled $1.37 billion, up 12.7% on a reported basis and 8.9% organically. ERP advance orders added an estimated 700 basis points to organic growth.
Advanced Wound Care sales rose 14.9% year over year to $537 million, with organic growth of 7.1%. Infection Prevention and Surgical Solutions revenues increased 11.3% year over year to $836 million, while organic sales advanced 10.1% on higher adoption of antimicrobial IV-site management products. Acera contributed $32 million and recorded 48% growth.
SOLV's Dental and HIS Sales Maintain Momentum
Dental Solutions revenues climbed 17% year over year to $396 million, while organic sales rose 15.2%. Advance ordering contributed about 10 percentage points, while new products supported underlying demand in restoratives and aesthetics.
Health Information Systems revenues increased 4.4% year over year to $354 million, with organic growth of 5.4%. Revenue cycle management solutions benefited from healthy customer retention and commercial execution. SOLV also announced its intent to separate Health Information Systems (HIS) to sharpen its MedTech focus and give the software business greater strategic flexibility.
Solventum Q2 Margin Analysis
Adjusted gross profit totaled $1.33 billion, up 9.8% year over year. As a percentage of revenues, the adjusted gross margin expanded 410 basis points to 60.1% from 56% in the prior-year quarter.
Selling, general and administrative expenses totaled $927 million, up 20.1% year over year, mainly due to higher separation-related and net legal costs. Research and development expenses declined 5.8% year over year to $178 million. Adjusted operating expenses totaled $701 million, down 4.8% from the year-ago quarter.
Adjusted operating income increased 32.3% year over year to $627 million. The adjusted operating margin expanded 650 basis points to 28.4%, primarily driven by the tariff refund and ERP-related advance-order timing benefits. Excluding these items, management estimated the adjusted operating margin at approximately 21.7%.
SOLV’s Financial Position
Solventum exited the second quarter with cash, cash equivalents and investments of $403 million compared with $561 million in the previous quarter.
Total assets increased to $14.2 billion from $14.1 billion in the previous quarter.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $38 million compared with $198 million in the year-ago period.
Solventum Raises Its 2026 Outlook
Solventum raised the lower end of its 2026 organic sales growth guidance. The company now expects sales to grow by 2.5-3% compared with the earlier guidance of 2-3%. Excluding an expected 100-basis-point SKU exit impact, the company now projects growth of 3.5-4%.
Adjusted earnings guidance increased to $7.10-$7.20 per share from the prior range of $6.40-$6.60. Free cash flow is now expected to be between $200 million and $300 million compared with the earlier estimate of about $200 million.
How Have Estimates Been Moving Since Then?
Since the earnings release, investors have witnessed a downward trend in estimates review.
VGM Scores
At this time, Solventum has a average Growth Score of C, a score with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Solventum has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Solventum is part of the Zacks Medical Services industry. Over the past month, Avantor, Inc. (AVTR - Free Report) , a stock from the same industry, has gained 15.3%. The company reported its results for the quarter ended June 2026 more than a month ago.
Avantor reported revenues of $1.69 billion in the last reported quarter, representing a year-over-year change of +0.5%. EPS of $0.21 for the same period compares with $0.24 a year ago.
For the current quarter, Avantor is expected to post earnings of $0.21 per share, indicating a change of -4.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
Avantor has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.
View the Zacks #1 Rank List
Image: Bigstock
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Solventum (SOLV - Free Report) . Shares have added about 11.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Solventum due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Solventum Corporation before we dive into how investors and analysts have reacted as of late.
Solventum Q2 Earnings & Revenues Beat Estimates
Solventum reported second-quarter 2026 adjusted earnings per share of $2.55, which beat the Zacks Consensus Estimate of $1.91 by 33.5%. The bottom line improved 50.9% year over year.
GAAP earnings per share in the quarter was 53 cents compared with 51 cents in the year-ago quarter.
SOLV's Sales Gain From Advance Ordering
Revenues of $2.21 billion rose 2.2% and surpassed the consensus mark of $2.17 billion by 2%. Organic sales increased 9.5%, aided by strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.
Reported growth included a 100-basis-point currency benefit and an 830-basis-point headwind from acquisitions and divestitures. The latter mainly reflected the September 2025 sale of the Purification and Filtration business, partly offset by the Acera acquisition.
Management estimated normalized organic growth of about 4%. This adjusts for roughly 630 basis points of ERP-related advance orders, partly offset by about 100 basis points of SKU rationalization headwinds and a partial separation-timing benefit.
Solventum's MedSurg Business Shows Strength
MedSurg revenues totaled $1.37 billion, up 12.7% on a reported basis and 8.9% organically. ERP advance orders added an estimated 700 basis points to organic growth.
Advanced Wound Care sales rose 14.9% year over year to $537 million, with organic growth of 7.1%. Infection Prevention and Surgical Solutions revenues increased 11.3% year over year to $836 million, while organic sales advanced 10.1% on higher adoption of antimicrobial IV-site management products. Acera contributed $32 million and recorded 48% growth.
SOLV's Dental and HIS Sales Maintain Momentum
Dental Solutions revenues climbed 17% year over year to $396 million, while organic sales rose 15.2%. Advance ordering contributed about 10 percentage points, while new products supported underlying demand in restoratives and aesthetics.
Health Information Systems revenues increased 4.4% year over year to $354 million, with organic growth of 5.4%. Revenue cycle management solutions benefited from healthy customer retention and commercial execution. SOLV also announced its intent to separate Health Information Systems (HIS) to sharpen its MedTech focus and give the software business greater strategic flexibility.
Solventum Q2 Margin Analysis
Adjusted gross profit totaled $1.33 billion, up 9.8% year over year. As a percentage of revenues, the adjusted gross margin expanded 410 basis points to 60.1% from 56% in the prior-year quarter.
Selling, general and administrative expenses totaled $927 million, up 20.1% year over year, mainly due to higher separation-related and net legal costs. Research and development expenses declined 5.8% year over year to $178 million. Adjusted operating expenses totaled $701 million, down 4.8% from the year-ago quarter.
Adjusted operating income increased 32.3% year over year to $627 million. The adjusted operating margin expanded 650 basis points to 28.4%, primarily driven by the tariff refund and ERP-related advance-order timing benefits. Excluding these items, management estimated the adjusted operating margin at approximately 21.7%.
SOLV’s Financial Position
Solventum exited the second quarter with cash, cash equivalents and investments of $403 million compared with $561 million in the previous quarter.
Total assets increased to $14.2 billion from $14.1 billion in the previous quarter.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $38 million compared with $198 million in the year-ago period.
Solventum Raises Its 2026 Outlook
Solventum raised the lower end of its 2026 organic sales growth guidance. The company now expects sales to grow by 2.5-3% compared with the earlier guidance of 2-3%. Excluding an expected 100-basis-point SKU exit impact, the company now projects growth of 3.5-4%.
Adjusted earnings guidance increased to $7.10-$7.20 per share from the prior range of $6.40-$6.60. Free cash flow is now expected to be between $200 million and $300 million compared with the earlier estimate of about $200 million.
How Have Estimates Been Moving Since Then?
Since the earnings release, investors have witnessed a downward trend in estimates review.
VGM Scores
At this time, Solventum has a average Growth Score of C, a score with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Solventum has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Solventum is part of the Zacks Medical Services industry. Over the past month, Avantor, Inc. (AVTR - Free Report) , a stock from the same industry, has gained 15.3%. The company reported its results for the quarter ended June 2026 more than a month ago.
Avantor reported revenues of $1.69 billion in the last reported quarter, representing a year-over-year change of +0.5%. EPS of $0.21 for the same period compares with $0.24 a year ago.
For the current quarter, Avantor is expected to post earnings of $0.21 per share, indicating a change of -4.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
Avantor has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.